Gastrinoma. New medical and surgical approaches.

Abstract

The clinical presentation of gastrinoma has changed since the original description by Zollinger and Ellison in 1955. Tumors currently found are smaller, extrapancreatic or extraintestinal in location, and frequently occult within lymph nodes. The incidence of hepatic metastases on initial presentation has decreased. In addition, the clinical course of patients with tumor in lymph nodes is benign, suggesting that more patients than were previously thought are now candidates for cure. Improved knowledge of the anatomic location of gastrinomas has enhanced our ability to find and remove them at laparotomy. As a result of these factors, more patients are being cured than ever before, and in the future, cure rate may be even higher. On the basis of these recent advances, the optimal treatment of gastrinoma is surgical excision for cure.

• Authors: T J Howard, E Passaro Jr
• Journal: The Surgical clinics of North America (Surg Clin North Am) Vol. 69 Issue 3 Pg. 667-81 (Jun 1989) ISSN: 0039-6109 [Print] United States
• PMID: 2567061 (Publication Type: Journal Article, Review)

Chemical References

• Anti-Ulcer Agents

Topics

• Anti-Ulcer Agents (therapeutic use)
• Gastrinoma (therapy)
• Humans
• Multiple Endocrine Neoplasia (therapy)
• Pancreatic Neoplasms (therapy)
• Zollinger-Ellison Syndrome (therapy)